#None #Intas Pharmaceuticals #Prothya Biosolutions #Accord Plasma

Accord Plasma B.V. Strengthens Global Plasma Processing Capabilities

On October 20, 2025, Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced its acquisition of Prothya Biosolutions Belgium BV, along with its subsidiaries. This strategic move aims to enhance Accord's commitment to global access to plasma-derived medications and strengthen its capacity to meet the increasing demand for essential plasma treatments worldwide.

Expanding Plasma Capabilities

Prothya Biosolutions stands as a leading plasma fractionation company in Europe, operating significant facilities in Amsterdam and Brussels, alongside plasma collection centers throughout Hungary. The company employs around 1,200 qualified professionals dedicated to advancing plasma treatment solutions.

The integration of Prothya into Accord's operations marks a significant expansion of Accord's plasma capabilities. By combining Prothya's proven expertise in Europe with Intas's large-scale fractionation infrastructure in India, the organization is set to accelerate the development and availability of essential plasma-derived drugs for patients in many regions around the world.

Paul Tredwell, the Global CEO of Accord Healthcare, expressed confidence in this strategic merger. “Our objective is to ensure that patients who rely on plasma-derived treatments can access reliable, high-quality solutions. With Prothya, we are better positioned to address the increasing global demand for plasma-derived medications, providing essential treatments often underused,” he stated.

A Focused Commitment to Healthcare

Accord Healthcare, headquartered in the UK, is one of the fastest-growing pharmaceutical companies in Europe, with an extensive portfolio of generics and biosimilars sold across more than 85 countries. This extensive market reach enables Accord to provide essential, affordable medications essential for national healthcare systems, helping healthcare professionals improve patients' lives worldwide.

Accord is committed to agility and innovation, continually pursuing product enhancements and increasing patient access. The company strives to think outside the box and deliver more value for the benefit of patients globally.

Overall, the acquisition of Prothya Biosolutions is expected to play a crucial role in meeting healthcare needs across various markets. It will facilitate even better access to vital treatments for those requiring plasma-derived pharmaceuticals, ultimately improving patient outcomes.

With this acquisition, Accord Plasma B.V. not only strengthens its operational capabilities but also reinforces its mission of prioritizing patient care and enhancing service delivery in the healthcare sector, allowing for widespread access to life-saving treatments worldwide.